Long Non-coding RNA MAFG-AS1 Promotes Cell Proliferation, Migration, and EMT by miR-3196/STRN4 in Drug-Resistant Cells of Liver Cancer.
MAFG-AS1
STRN4
liver cancer
long non-coding RNA
miR-3196
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
03
2021
accepted:
21
06
2021
entrez:
13
8
2021
pubmed:
14
8
2021
medline:
14
8
2021
Statut:
epublish
Résumé
Long non-coding RNAs (lncRNAs) have been shown to participate in the development and progression of several different types of cancer. Past studies indicated that lncRNA MAFG-antisense 1 (AS1) promotes colorectal cancer. However, the role of MAFG-AS1 in hepatocellular carcinoma (HCC) remains unclear. The aim of the present study is to examine the effect of lncRNA MAFG-AS1 on drug resistance HCC. The results indicated that MAFG-AS1 is upregulated in drug-resistant cells. Further, MAFG-AS1 promotes growth and migration of HCC by upregulating STRN4 through absorbing miR-3196. Thus, LncRNA MAFA-AS1 may become a novel target to treat HCC patients.
Identifiants
pubmed: 34386494
doi: 10.3389/fcell.2021.688603
pmc: PMC8353155
doi:
Types de publication
Journal Article
Langues
eng
Pagination
688603Informations de copyright
Copyright © 2021 Chen, Huang and Pan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Cycle. 2020 Mar;19(5):601-609
pubmed: 32079456
Clin Mol Hepatol. 2017 Dec;23(4):273-279
pubmed: 29151326
Br J Cancer. 2010 Nov 9;103(10):1617-26
pubmed: 20978511
Cancer Cell. 2014 May 12;25(5):666-81
pubmed: 24768205
Eur Rev Med Pharmacol Sci. 2016 May;20(10):2020-7
pubmed: 27249600
Gastroenterology. 2011 May;140(5):1629-41.e15
pubmed: 21320503
Oncogene. 2016 Mar 24;35(12):1575-84
pubmed: 26073087
Oncotarget. 2017 Jul 31;8(35):59417-59434
pubmed: 28938647
Oncol Rep. 2016 Nov;36(5):2673-2680
pubmed: 27666964
Am J Gastroenterol. 2014 Apr;109(4):542-53
pubmed: 24513805
Oncol Lett. 2017 Sep;14(3):2831-2837
pubmed: 28928822
Oncol Res. 2017 Sep 21;25(8):1329-1340
pubmed: 28256185
Cell Death Dis. 2017 Oct 12;8(10):e3104
pubmed: 29022920
Nat Med. 2017 Oct;23(10):1167-1175
pubmed: 28920960
Biochem Biophys Res Commun. 2017 Mar 11;484(3):514-521
pubmed: 28115163
Biochem Biophys Res Commun. 2018 Nov 17;506(1):251-258
pubmed: 30348529
Cancer Lett. 2017 Dec 28;411:117-129
pubmed: 28987388
FEBS Lett. 2014 Jan 21;588(2):377-82
pubmed: 24140348
Cancer Cell Int. 2020 Oct 19;20:511
pubmed: 33093810
J Exp Clin Cancer Res. 2018 Nov 27;37(1):289
pubmed: 30482236
Cancer Lett. 2014 Apr 10;345(2):230-4
pubmed: 23941829
J Hepatol. 2018 Apr;68(4):646-654
pubmed: 29155019
Am J Cancer Res. 2016 Oct 01;6(10):2299-2309
pubmed: 27822419
Burns. 2011 Jun;37(4):665-72
pubmed: 21236582
Funct Integr Genomics. 2018 May;18(3):261-275
pubmed: 29374362
Am J Cancer Res. 2017 Apr 01;7(4):770-783
pubmed: 28469952